SYRE — Spyre Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology
$87.38
-$1.12 (-1.27%)
Spyre Therapeutics Inc. (SYRE) is a biotechnology company listed on NASDAQ. It is led by Cameron Turtle DPHIL, Ph.D., based in Building 23, Waltham, MA, United States, 02453, with about 112 employees. Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Net income was -$11.2M. SYRE currently screens at market cap $7.60B.
Use this SYRE page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SYRE quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SYRE SEC filings page. Lician reads the product cache first so this HTML stays unique to Spyre Therapeutics Inc. even when a live quote feed is slow.
About Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
SYRE Key Statistics
Market Cap
$7.60B
Volume
808,012
Previous Close
$106.65
Day Range
$106.94 – $110.15
P/B Ratio
14.75
EPS
$0.00
Revenue
$0.00
Net Income
-$208.02M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-100.0%
Employees
112
SYRE Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $886.00K | $2.33M | $18.74M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$208.02M | -$338.79M | -$83.81M | -$65.80M |
| EPS (Diluted) | $0.00 | -$49.12 | -$24.86 | -$25.02 |
Total Assets
$608.48M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$89.42M
Operating Cash Flow
-$157.41M
Free Cash Flow
$0.00
Spyre Therapeutics Inc. Company Information
- CEO & Director
- Cameron Turtle DPHIL, Ph.D.
- Headquarters
- Building 23, Waltham, MA, United States, 02453
- Website
- www.spyre.com
- Phone
- 617 651 5940
- IPO / Founded
- 2016-04-07
- Sector
- Healthcare
- Industry
- Biotechnology